Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows:

- oncology (36.8%);

- respiratory diseases (22.9%);

- cardiovascular, renal and metabolic diseases (18.6%);

- other (21.7%): inflammatory and autoimmune diseases, neurological diseases, gastrointestinal and infectious diseases.

Net sales are distributed geographically as follows: the United Kingdom (2%), Continental Europe (16.5%), Americas (38.3%) and Africa/Asia/Australia (43.2%).

Number of employees : 70 600 people.
Sales per Business
20182019Delta
GBP (in Million)%GBP (in Million)%
Oncology4,52127.3%6,79435.5% +50.28%
Cardiovascular, Renal & Metabolism5,03230.4%5,41328.3% +7.57%
Respiratory3,68322.2%4,22622.1% +14.74%
Other Diseases2,55015.4%2,03910.7% -20.04%
Externalisation Revenue780.714.7%641.983.4% -17.77%
Sales per region
2019
GBP (in Million)%
United States6,30833%
China3,81520%
Japan1,97710.3%
United Kingdom1,4287.5%
Other Asia, Africa and Australasia1,1125.8%
Other Continental Europe1,0125.3%
Sweden653.743.4%
Other Americas638.063.3%
Germany551.842.9%
France453.072.4%
Managers
NameAgeSinceTitle
Pascal Soriot602012Chief Executive Officer & Executive Director
Leif Johansson682012Non-Executive Chairman
Pam Cheng482015Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer672013Chief Financial Officer & Executive Director
Menelas N. Pangalos, Dr.-2019EVP-Biopharmaceuticals Research & Development
José Baselga, Dr.58-Executive VP-Oncology Research & Development
Henry D. Cremisi, Dr.--Medical Director
Marcus Wallenberg631999Independent Non-Executive Director
Graham Chipchase562019Senior Independent Non-Executive Director
Geneviéve B. Berger, Dr.642012Independent Non-Executive Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,312,278,985 1,256,302,343 95.7% 0 0.0% 95.7%
Shareholders
NameEquities%
Investor AB (Investment Company) 51,587,810 3.93%
BlackRock Investment Management (UK) Ltd. 42,170,900 3.21%
The Vanguard Group, Inc. 41,557,084 3.17%
Capital Research & Management Co. (World Investors) 41,526,368 3.16%
Wellington Management Co. LLP 38,725,550 2.95%
Norges Bank Investment Management 30,892,000 2.35%
Legal & General Investment Management Ltd. 27,994,000 2.13%
BlackRock Fund Advisors 24,473,056 1.86%
Fidelity Management & Research Co. LLC 19,388,414 1.48%
BlackRock Advisors (UK) Ltd. 16,929,060 1.29%
Holdings
NameEquities%Valuation
AstraZeneca Pharma India Limited (506820) 18,750,00075.0%881,007,563 USD
Viela Bio, Inc. (VIE) 14,650,33426.8%634,652,469 USD
Swedish Orphan Biovitrum AB (SOBI) 24,193,0928.06%558,822,442 USD
ADC Therapeutics SA (ADCT) 3,811,2155.39%178,402,974 USD
Innate Pharma (IPH) 7,485,5009.49%46,618,721 USD
Circassia Group Plc (CIR) 71,060,74118.9%21,621,652 USD
PhaseBio Pharmaceuticals, Inc. (PHAS) 3,004,55410.4%13,820,948 USD
Entasis Therapeutics Holdings Inc. (ETTX) 2,164,85514.8%6,407,971 USD
Markets and indexes
- London Stock Exchange, SETS
- Main Market
- FTSE 100 / FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, OMX Stockholm 30, Stoxx Europe 50, Stoxx Global 200, Stoxx UK 50
Stock Exchange Codes
- Bloomberg Code :  AZN:LN
- Reuters Code :  AZN.L
- Datastream Code :  AZN
Company contact information
AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA Cambridge, Cambridgeshire
United Kingdom

Phone : +44 (0)20 3749 5000
Fax : +44 (0)20 7604 8151
Internet : http://www.astrazeneca.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of AstraZeneca PLC
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
ASTRAZENECA PLC11.13%145 125
JOHNSON & JOHNSON1.87%391 238
ROCHE HOLDING AG0.06%294 334
PFIZER, INC.-1.86%213 662
MERCK & CO., INC.-10.92%204 919
NOVARTIS AG-17.85%182 240
ABBVIE INC.4.95%163 988
NOVO NORDISK A/S5.20%150 040
AMGEN INC.-0.16%140 971
ELI LILLY AND COMPANY16.36%138 627
BRISTOL-MYERS SQUIBB COMPANY-4.94%137 535
SANOFI-2.50%129 396
GLAXOSMITHKLINE PLC-12.58%101 059
CHUGAI PHARMACEUTICAL CO., LTD.43.57%74 916
JIANGSU HENGRUI MEDICINE CO., LTD.25.05%69 163
BAYER AG-23.13%64 812
ALLERGAN PLC0.97%63 659
DAIICHI SANKYO COMPANY, LIMITED29.00%57 088
TAKEDA PHARMACEUTICAL COMPANY LIMITED-12.12%56 221
ASTELLAS PHARMA INC.-11.58%29 018
CHANGCHUN HIGH & NEW TECHNOLOGY INDUSTRY (GROUP) INC.116.64%28 124